Support: 888-992-3836
Copyright © 2023 InvestorsHub Inc.
Replies to post #10 on Aligos Therapeutics Inc (ALGS)
DewDiligence
02/08/23 6:09 PM
#20 RE: DewDiligence #10
Aligos Therapeutics…today announced a portfolio reprioritization. Aligos’ highest priorities will be focused on rapid advancement of its clinical NASH (ALG-055009) and COVID-19 (ALG-097558) programs as well as maintaining its ongoing NASH oligonucleotide research collaborations with Merck… Additionally, the Company plans to complete the <=48-week (ALG-000184) and single ascending dose (ALG-125755) cohorts for its two chronic hepatitis B programs and continue to invest in selected research programs and collaborations with external research organizations. This portfolio reprioritization is being accompanied by a reduction of the Company’s current workforce of approximately 10%... …As a result of the portfolio reprioritization, realignment of its workforce, and other cost-saving measures, the Company expects to maintain a strong balance sheet and extend its projected cash runway to the end of 2024.